Compare Novo Nordisk A/S (NVO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Paychex, Inc. — how do they compare? Novo Nordisk A/S trades at $38.45 (market cap $165.31B), while Paychex, Inc. trades at $104.47 (market cap $37.19B). The key difference: Novo Nordisk A/S is far larger — about 4.4× Paychex, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Paychex, Inc. for 56 Days on average.
| NVO | PAYX | |
|---|---|---|
Market Cap | $165.31B | $37.19B |
Volume | 11,432,838 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $63.98 | $128.59 |
52-Week Low | $35.29 | $85.57 |
Typical Hold Time | 116 Days | 56 Days |
Enterprise Value | $179.56B | $40.87B |
Dividend Yield | 4.71% | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Paychex (PAYX) trades at $104.62, up 3.02% today, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.34 beating the $1.32 estimate, and maintains robust profitability with a 27.35% net income margin. Recent news highlights a 14% stock decline despite earnings strength, raising questions about dividend sustainability amid investor focus on cash flow.
The outlook is cautiously optimistic, with a consensus price target of $111 suggesting modest upside. Key opportunities include steady revenue growth and high margins, but risks involve labor market sensitivity and elevated valuation multiples. The stock's recent volatility reflects divergent analyst views, with 67.74% holding a neutral rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
